NCT04379635 2026-03-18
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
BeOne Medicines
Phase 3 Active not recruiting
BeOne Medicines
RemeGen Co., Ltd.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
ImmunityBio, Inc.
BeiGene
BeiGene
Sun Yat-sen University
BeiGene
BeiGene
Tianjin Medical University Cancer Institute and Hospital
BeiGene
Akeso
Novartis
Celgene